FDA Sends Back Filing For Pfizer's Tafamidis, Acquired in FoldRx Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Two months after Pfizer files an NDA for the orphan drug, the agency issues a Refusal To File Letter requesting more information.
You may also be interested in...
Pfizer Vyndaqel Advisory Committee Pits Orphan Flexibility Vs. Data Shortcomings
FDA finds much to question in a single pivotal trial of Pfizer’s orphan drug Vyndaqel (tafamidis meglumine) for familial amyloid polyneuropathy, but the ultra-orphan nature of the disease may outweigh those concerns.
European HTA Highlights: Discounts Soften NICE Approach But Germany’s IQWiG Shows Its Teeth
It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.
Pfizer Rare Disease Plans Back On Track With Resubmission of Tafamidis
Pfizer gained the therapy to treat a rare genetic neurologic disorder in its 2010 acquisition of folded protein company FoldRx.